1. Home
  2. RMCF vs SKYE Comparison

RMCF vs SKYE Comparison

Compare RMCF & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rocky Mountain Chocolate Factory Inc.

RMCF

Rocky Mountain Chocolate Factory Inc.

HOLD

Current Price

$0.65

Market Cap

7.0M

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

SELL

Current Price

$1.00

Market Cap

6.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
RMCF
SKYE
Founded
1981
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0M
6.4M
IPO Year
2024
2013

Fundamental Metrics

Financial Performance
Metric
RMCF
SKYE
Price
$0.65
$1.00
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
★ $9.00
AVG Volume (30 Days)
25.5K
★ 102.2K
Earning Date
10-19-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 34.88
N/A
EPS
★ N/A
N/A
Revenue
★ $30,432,352.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.66
$0.26
52 Week High
$2.99
$11.04

Technical Indicators

Market Signals
Indicator
RMCF
SKYE
Relative Strength Index (RSI) 27.72 40.41
Support Level N/A $0.50
Resistance Level $1.19 $1.66
Average True Range (ATR) 0.06 0.21
MACD -0.01 0.01
Stochastic Oscillator 0.08 52.38

Price Performance

Historical Comparison
RMCF
SKYE

About RMCF Rocky Mountain Chocolate Factory Inc.

Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The company prepares numerous products, including caramel apples in the store. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, and Others. The company derives maximum revenue through manufacturing activities. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: